Literature DB >> 18952751

Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.

M J Soto-Cárdenas1, G Pelayo-García, A Rodríguez-Camacho, E Segura-Fernández, A Mogollo-Galván, J A Giron-Gonzalez.   

Abstract

We analyzed the principal risk factors of venous thromboembolism (VTE) (immobilization, recent surgery and previous VTE), prophylaxis with low-molecular weight heparin (LMWH) and complications (i.e. severe bleeding, recurrence and death). Patients with advanced cancer under palliative care (PC) and with VTE, were reviewed during the three years before the study. 71 Patients were diagnosed with VTE. 88.7% were outpatients. The risk factors present were: immobilizations in 28 patients (39.4%), recent surgery in 5 (7%) and previous VTE in 23 (32.5%). Prophylaxis was used in 4 (14.3%) patients with immobilization, no patient with recent surgery, and 10 (43.4%) patients with previous VTE. After diagnosis, all patients received treatment with LMWH in therapeutic dosage. The complications observed were: 6 recurrences (8.5%), 11 VTE-related deaths (15.5%), and bleeding events occured in 8 cases (11.3%), 4 (5.6%) of whom suffered severe bleeding; of these patients, 3 (4.2%) died as a result of the bleeding events. In PC patients with advanced cancer, VTE is a serious complication that conditions control of symptoms. The presence of other risk factors, immobilization and previous VTE, is common and LMWH prophylaxis is limited in clinical practice. The risks vs benefits of anticoagulation need to be counterbalanced.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18952751     DOI: 10.1177/0269216308098803

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  9 in total

1.  Withdrawing medication: managing medical comorbidities near the end of life.

Authors:  Christopher P O'Brien
Journal:  Can Fam Physician       Date:  2011-03       Impact factor: 3.275

2.  Predictors of anticoagulation in hospice patients with lung cancer.

Authors:  Holly M Holmes; Kevin T Bain; Ali Zalpour; Ruili Luo; Eduardo Bruera; James S Goodwin
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

Review 3.  [Anticoagulation in the elderly].

Authors:  J Harenberg; R Bauersachs; C Diehm; H Lawall; H Burkhardt; H Gerlach; H Darius; H Völler; E Rabe; M Wehling
Journal:  Internist (Berl)       Date:  2010-11       Impact factor: 0.743

Review 4.  Deprescribing in Palliative Cancer Care.

Authors:  Christel Hedman; Gabriella Frisk; Linda Björkhem-Bergman
Journal:  Life (Basel)       Date:  2022-04-20

Review 5.  Decision making about change of medication for comorbid disease at the end of life: an integrative review.

Authors:  Ronald T C M van Nordennen; Jan C M Lavrijsen; Kris C P Vissers; Raymond T C M Koopmans
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

Review 6.  Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care.

Authors:  Silvia Riondino; Patrizia Ferroni; Girolamo Del Monte; Vincenzo Formica; Fiorella Guadagni; Mario Roselli
Journal:  Cancers (Basel)       Date:  2020-05-06       Impact factor: 6.639

7.  Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study.

Authors:  Siwan Seaman; Annmarie Nelson; Simon Noble
Journal:  Patient Prefer Adherence       Date:  2014-04-08       Impact factor: 2.711

8.  Assessment of the Palliative Prognostic Index in hospitalized oncologic patients treated by a palliative care team: impact of acute concomitant diseases.

Authors:  Carmen Palomar-Muñoz; Marina Martín-Zamorano; Amparo Mogollo; Susana Pascual-Pérez; Inmaculada Rodríguez-Morales; José-Antonio Girón-González
Journal:  Oncotarget       Date:  2018-04-10

Review 9.  Thromboprophylaxis in the End-of-Life Cancer Care: The Update.

Authors:  Ewa Zabrocka; Ewa Sierko
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.